Atara biotherapeutics reports inducement grants under nasdaq listing rule 5635(c)(4)

South san francisco, calif.--(business wire)--atara biotherapeutics, inc. (nasdaq: atra), a leader in t-cell immunotherapy, leveraging its novel allogeneic ebv t-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of an aggregate of 37,538 restricted stock units of atara's common stock to five newly hired employees. these awards were approved by the compensation committee of atara's board of directors and granted under the
ATRA Ratings Summary
ATRA Quant Ranking